RBC Capital Initiates Coverage On Avidity Biosciences with Outperform Rating, Announces Price Target of $67

Benzinga · 11/26 09:53
RBC Capital analyst Luca Issi initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Outperform rating and announces Price Target of $67.